Table 1.

The primers used for real-time reverse transcription-PCR and the comparison of fold changes tested by reverse transcription-PCR and Western blot analysis

GenesPrimer sequencePCR product (bp)Fold change tested by reverse transcription-PCRFold change tested by Western blot
Cathepsin Ccgg ctt ccc ata cct tat cct tca ttt tgc atg gag104−2.8 (PC-3/D+E)−5.5 (PC-3/D+E)
Cathepsin Kaat cca tcc tgc tct tcc cca act ccc ttc caa agt684.2 (PC-3/D+E)3.6 (PC−3/D+E)
Annexin A2ggc aaa ggg tag aag agc tca tag aga tcc cga gca783.8 (LN/D+E)2.3 (LN/D+E)
ATF5ctc ctc ctt ctc cac ctc aa gcc gac ttg ttc tgg tct ct103−2.78 (PC-3/D+E)
Cyclin A2aat cag ttt ctt acc caa tac ctg atg gca aat act tga127−2.7 (LN/D+E)−3.2 (LN/D+E)
Fas/Apo-1caa aag tgt taa tgc cca agt gca gtc tgg ttc atc cc1876.2 (LN/D)
FOXM1gcc aca ctt agc gag acc c atc aca agc att tcc gag aca189−5.5 (LN/D+E)
GADD45cgc ctg tga gtg agt gc ctt atc cat cct ttc ggt ctt1541.9 (LN/D+E)
IGFBP2atg ggc gag ggc act t cag ctc ctt cat acc cga ctt189−2.8 (LN/D)
uPAggg agc aga gac act aac gac t ctc aca gcc cac aca aca ag1081.7 (PC-3/D+E)
Ki-67ccg ggc tcc atc atc t ctc cag acg cca aaa taa gac148−4.3 (PC-3/D)
p21WAF1ctg gag act ctc agg gtc gaa gga tta ggg ctt cct ctt gga983.1 (PC-3/D)2.1 (PC-3/D)
p27KIP1cgc tcg cca gtc cat t aca aaa ccg aac aaa aca aag1875.4 (PC-3/D+E)2.8 (PC-3/D+E)
PIRcac tag ccc tcc atc ctc tac ggg tct gcc aat gct tct151−4.1 (PC-3/D)
MMP1gct ttc ctc cac tgc tgc t aac ttg cct ccc atc att ctt1462.1 (PC-3/E)
STK6tca gcg ggt ctt gtg t ctc ttt tgg gtg tta ttc agt162−2.1 (LN/D+E)
Survivincca ctg ccc cac tga gaa c acc gga cga atg ctt ttt atg118−3.7 (LN/T+E)−3.1 (LN/T+E)
TRIP13tct ggc agt gga caa gca gtt tgg gag acg gct gtg tgg136−4.6 (LN/D)
GAPDHctg cac cac caa ctg ctt ag ttc agc tca ggg atg acc tt222
β-Actincca cac tgt gcc cat cta cg agg atc ttc atg agg tag tca gtc ag99
  • NOTE: Fold change, positive values (increase); negative values (decrease). All samples were treated for 72 hours. PC-3/D+E, PC-3 cells treated with a combination of docetaxel and estramustine; LN/D+E, LNCaP cells treated with a combination of docetaxel and estramustine; PC-3/D, PC-3 cells treated with docetaxel alone; LN/D, LNCaP cells treated with docetaxel alone.